Photo taken from ASCO/X
May 25, 2024, 10:20
An ASCO 24 Educational Session will review accelerated approval of lifileucel in advanced melanoma
ASCO (American Society of Clinical Oncology) shared on X:
“Accelerated approval of lifileucel in advanced melanoma is first T-cell Treatment approved for solid tumors.
An ASCO24 Educational Session will review supporting evidence, discuss practical considerations for clinic use, and more.”
Source: ASCO/X
The American Society of Clinical Oncology (ASCO) is a leading professional organization representing nearly 45,000 physicians and oncology specialists worldwide, dedicated to cancer care.
Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, ASCO is committed to advancing cancer research, education, prevention, and high-quality patient care.